Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of “Moderate Buy” from Analysts

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has received a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $8.50.

A number of brokerages recently weighed in on RANI. Maxim Group boosted their price objective on shares of Rani Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, October 20th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Rani Therapeutics in a report on Friday, January 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rani Therapeutics in a report on Monday, December 29th.

Rani Therapeutics Price Performance

Shares of Rani Therapeutics stock opened at $1.38 on Wednesday. The business’s fifty day moving average is $1.46 and its two-hundred day moving average is $1.09. Rani Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $3.87. The firm has a market cap of $167.68 million, a PE ratio of -1.75 and a beta of 0.42.

Rani Therapeutics (NASDAQ:RANI) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.03). Equities research analysts anticipate that Rani Therapeutics will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RANI. Armistice Capital LLC acquired a new position in shares of Rani Therapeutics during the 2nd quarter worth about $1,619,000. Citadel Advisors LLC lifted its stake in Rani Therapeutics by 199.0% in the 3rd quarter. Citadel Advisors LLC now owns 452,542 shares of the company’s stock valued at $226,000 after purchasing an additional 301,193 shares during the last quarter. Kestra Private Wealth Services LLC raised its position in shares of Rani Therapeutics by 44.8% in the third quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company’s stock valued at $113,000 after purchasing an additional 70,002 shares during the period. CWA Asset Management Group LLC lifted its holdings in shares of Rani Therapeutics by 80.0% during the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company’s stock worth $75,000 after buying an additional 66,667 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in shares of Rani Therapeutics by 102.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company’s stock valued at $28,000 after acquiring an additional 28,000 shares during the period. 30.19% of the stock is currently owned by institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.